Jump to Content

Myriad Genetics, Inc.

24 days left to seek lead plaintiff status

Case Summary

Company Name
Myriad Genetics, Inc.
Stock Symbol
Class Period
August 13, 2014 to March 12, 2018
Motion Deadline
June 19, 2018
District of Utah

The complaint charges Myriad and certain of its officers with violations of the Securities Exchange Act of 1934.  Myriad develops and markets molecular diagnostic products to provide physicians with information to help guide the care of their patients, prevent disease, delay the onset of disease, and catch disease at an early stage.  Myriad purports to employ a variety of proprietary techniques designed to provide an understanding of the genetic basis of disease and the role of genes in the onset, progression and treatment of disease.

Established in 1978, the Healthcare Common Procedure Coding System (“HCPCS”) provides a standardized coding system for describing the specific items and services provided in healthcare.  HCPCS dictates the billing codes for claims that physicians, healthcare providers and suppliers, such as Myriad, submit to the Centers for Medicare and Medicaid Services (“CMS”).  The National Correct Coding Initiative (“NCCI”), a CMS program designed to prevent improper payment for procedures that should not be submitted together, provides further instruction with respect to correct billing practices.  Among other things, the NCCI provides that billing documents must contain numerical code pairs, reflected in adjacent columns, identifying the services provided.  As CMS has stated in its billing guidance documents, “[t]he underlying principle is that the second code defines a subset of the work of the first code.  Reporting the codes separately is inappropriate.  Separate reporting would trigger a separate payment and would constitute double billing.”

In September 2013, Myriad launched its proprietary 25-gene myRisk Hereditary Cancer test (“myRisk”), which includes testing for multiple genes associated with cancer, including BRCA1 and BRCA2, both of which are associated with breast and ovarian cancer.  BRCA1 and BRCA2 genetic testing—specifically, BRCA sequencing and BRCA duplication-deletion—are represented in HCPCS by codes 81211 and 81213.  CMS has clearly stated that codes 81211 and 81213 are not correctly used together in claim submissions.

The complaint alleges that, throughout the Class Period, defendants made materially false and misleading statements regarding the Company’s business, operations and compliance policies, including that Myriad was submitting false or otherwise improper claims for payment under Medicare and Medicaid for the Company’s myRisk cancer testing, which conduct would foreseeably subject Myriad to heightened regulatory scrutiny and/or enforcement action, and that, as a consequence, Myriad’s revenues from its myRisk cancer testing were in part the product of improper conduct and, therefore, unlikely to be sustainable.  As a result of this improper conduct, the price of Myriad stock was artificially inflated during the Class Period, reaching a high of over $45 per share.

Then on March 12, 2018, after the market closed, Myriad disclosed that it had received a subpoena from the Department of Health and Human Services, Office of Inspector General, in connection with its “investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid.” The subpoena specifically related to Myriad’s myRisk cancer testing and covered a time period from January 1, 2014 – less than four months after the September 2013 launch of Myriad’s myRisk test – through the date of the subpoena’s issuance.  On this news, the price of Myriad stock fell $4.01 per share, or more than 12%, to close at $29.01 per share on March 13, 2018.

Class Period: August 13, 2014 - March 12, 2018
Main Menu { Banner Image }